CJC-1295 vs Sermorelin

Overview

CJC-1295 and Sermorelin are both synthetic analogues of growth hormone-releasing hormone (GHRH), the endogenous peptide that signals the pituitary gland to produce and release growth hormone. They both work through the same receptor — the GHRH receptor on pituitary somatotroph cells — but their structural differences give them significantly different pharmacokinetic profiles and practical characteristics.

Sermorelin (GRF 1-29) is the original truncated GHRH analogue, consisting of the first 29 amino acids of natural GHRH. CJC-1295 is a modified version with amino acid substitutions that improve stability. CJC-1295 also exists in a form with a Drug Affinity Complex (DAC) that dramatically extends its half-life.

Quick Comparison Table

The Key Difference: Stability and Half-Life

The fundamental difference between these two peptides comes down to structural stability. Natural GHRH degrades in minutes once released into the bloodstream, broken down by enzymes (particularly dipeptidyl peptidase-IV). Sermorelin, being the native 1-29 fragment, shares this vulnerability and has a half-life of roughly 10-20 minutes.

CJC-1295 without DAC (Modified GRF 1-29) addresses this with four amino acid substitutions at positions 2, 8, 15, and 27. These changes make it significantly more resistant to enzymatic degradation, extending the half-life to approximately 30 minutes. While this might seem modest, it results in a meaningfully larger and more sustained GH pulse.

CJC-1295 with DAC takes this further. The Drug Affinity Complex allows the peptide to bind covalently to albumin in the blood, creating a circulating reservoir. This extends the effective half-life to 6-8 days, meaning a single injection produces sustained GH elevation for nearly a week.

Clinical History: Sermorelin Has the Edge

Sermorelin has a significant advantage in clinical provenance. It was approved by the FDA in 1997 as Geref® for diagnosing and treating growth hormone deficiency in children. This means it has a documented safety and efficacy record from regulated clinical trials and post-market use. Its discontinuation in 2008 was for business reasons, not safety concerns.

CJC-1295 underwent Phase I and Phase II clinical trials that demonstrated its ability to significantly increase GH and IGF-1 levels. However, clinical development was halted. One subject in a clinical trial experienced an adverse event, though the circumstances and direct attribution have been debated in the research community.

Practical Considerations for Research

Sermorelin Advantages

• Clinical pedigree: Former FDA-approved status provides more regulatory confidence
• Physiological GH pattern: Very short half-life means it produces the most natural-looking GH pulse
• Canadian availability: Can be obtained through compounding pharmacies with a physician prescription
• Most conservative option: Closest to natural GHRH signalling

CJC-1295 Advantages

• Greater GH output: Longer half-life means a larger total GH release per dose
• Canadian origin: Developed by ConjuChem Biotechnologies in Montreal
• Dosing convenience (with DAC): Once-weekly administration possible
• Better studied in combination: More modern research data on CJC-1295 + Ipamorelin synergy

Which Is Better for GHRP Combination Research?

Both CJC-1295 (without DAC) and Sermorelin are commonly combined with growth hormone releasing peptides like Ipamorelin. The combination of a GHRH analogue (which "primes" the pituitary) and a GHRP (which "triggers" GH release and suppresses somatostatin) produces synergistic results — a GH pulse significantly larger than either compound alone. For a deeper look at how these combinations work, see our peptide synergy guide.

CJC-1295 without DAC is the more popular choice for this combination in current research because its slightly longer half-life provides a larger synergistic window. However, Sermorelin + Ipamorelin is also well-documented and may be preferred when a more physiological, shorter-duration pulse is desired.

Canadian Regulatory Context

In Canada, Sermorelin has a clear advantage: it can be legally prescribed by physicians and prepared by licensed compounding pharmacies. CJC-1295 is available only through research chemical suppliers and has no prescribing framework. For research conducted under medical supervision, Sermorelin offers a more regulated pathway. Read our full legality guide for details on Canadian peptide regulations. Both are considered banned by WADA for competitive athletes. For a broader comparison of GH secretagogues including Ipamorelin and Hexarelin, see our secretagogues overview.

Bottom Line for Researchers

• Want the most clinical evidence and regulated access? Sermorelin — with its FDA history and compounding pharmacy availability in Canada.
• Want maximum GH output per dose? CJC-1295 without DAC — its improved stability generates a larger GH pulse.
• Want sustained GH elevation with less frequent dosing? CJC-1295 with DAC — though this produces less physiological GH patterns.
• Want the most natural GH pulse? Sermorelin — its short half-life most closely mimics natural GHRH signalling.